pamidronate has been researched along with Body Weight in 26 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with the severe forms of osteogenesis imperfecta have in several studies been treated with intravenous pamidronate, but there are only few reports of the effect of early treatment." | 9.12 | Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. ( Aström, E; Jorulf, H; Söderhäll, S, 2007) |
| "Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth." | 7.72 | Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| " The time course study on the antihypercalcemic effect of pamidronate was performed using a rat hypercalcemia model induced by orally administered cholecalciferol." | 7.68 | Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol. ( Hasegawa, Y; Inukai, T; Noguchi, S; Okada, M, 1992) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 6.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Pamidronate did not inhibit MMP-2 activation but attenuated oxidative stress and improved myocardial energetic metabolism." | 5.43 | Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats. ( Alegre, PH; Antonio, L; Azevedo, PS; Bergamasco, CM; Carvalho, PB; Fernandes, AA; Gonçalves, AF; Minicucci, MF; Modesto, PN; Paiva, SA; Polegato, BF; Roscani, MG; Zornoff, M, 2016) |
| "Children with the severe forms of osteogenesis imperfecta have in several studies been treated with intravenous pamidronate, but there are only few reports of the effect of early treatment." | 5.12 | Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. ( Aström, E; Jorulf, H; Söderhäll, S, 2007) |
| "Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth." | 3.72 | Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| " The time course study on the antihypercalcemic effect of pamidronate was performed using a rat hypercalcemia model induced by orally administered cholecalciferol." | 3.68 | Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol. ( Hasegawa, Y; Inukai, T; Noguchi, S; Okada, M, 1992) |
| "Pamidronate treatment had positive effects on skeletal muscle in the Mdx mice with decreased serum and muscle creatine kinase and evidence of improved muscle histology and grip strength." | 2.82 | Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy. ( Grynpas, MD; Mitchell, J; Sugamori, KS; Yoon, SH, 2016) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 2.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Pamidronate treatment protected mice from cortical bone loss but did not increase bone strength." | 1.43 | Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2016) |
| "Pamidronate did not inhibit MMP-2 activation but attenuated oxidative stress and improved myocardial energetic metabolism." | 1.43 | Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats. ( Alegre, PH; Antonio, L; Azevedo, PS; Bergamasco, CM; Carvalho, PB; Fernandes, AA; Gonçalves, AF; Minicucci, MF; Modesto, PN; Paiva, SA; Polegato, BF; Roscani, MG; Zornoff, M, 2016) |
| "Pamidronate (0." | 1.33 | Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet. ( Ammann, P; Mekraldi, S; Rizzoli, R; Toromanoff, A, 2005) |
| "The alendronate-treated group did not show significant alteration of the breaking load or the cross-sectional shape of the femoral midshaft." | 1.30 | Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. ( Azuma, Y; Kanatani, H; Kiyoki, M; Komoriya, K; Ohta, T; Oue, Y, 1998) |
| "PTHrP stimulates osteoclastic bone resorption and renal calcium reabsorption through the activation of a receptor similar to that of PTH (PTH-R)." | 1.30 | Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors. ( Bouizar, Z; de Vernejoul, MC; Denne, MA; Morieux, C; Ureña, P; Yaghoobian, J, 1998) |
| "The accelerated osteoclastic bone resorption induced by rhG-CSF was suppressed by the pharmacological activity of AHPrBP." | 1.30 | The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate. ( Adachi, K; Doi, K; Nakayama, H; Sugimoto, T; Suzuki, M, 1999) |
| "To test the role of bone resorption in the response of the bone to mechanical stimulation, we compared the anabolic response to a single period of loading, of rats treated with 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP) or vehicle." | 1.29 | Stimulation of bone formation by dynamic mechanical loading of rat caudal vertebrae is not suppressed by 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP). ( Chambers, TJ; Chow, JW; Jagger, CJ, 1995) |
| "Pamidronate (APD) is a bisphosphonate that prevents bone loss from a variety of causes." | 1.29 | Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats. ( Dresner-Pollak, R; Greenspan, SL; Gundberg, C; Hock, JM; Maitland, LA; Middlebrooks, VL; Moses, AC; Rosen, HN; Sullivan, EK; Zeind, AJ, 1993) |
| " The experimental conditions provide a technically simple method which is sensitive enough to examine antiresorptive properties in a healthy animal and to detect adverse effects on the kidney." | 1.28 | Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. ( Eitan, Y; Golomb, G; Hoffman, A, 1992) |
| " The LD50 of i." | 1.27 | Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. ( Blum, H; Möller, H; Pittermann, W; Pool, BL; Schmähl, D; Sinn, HJ; Spring, H; Sterz, H; Wingen, F, 1986) |
| " Serum calcium and 1,25-dihydroxyvitamin D levels remained normal at all dosage levels." | 1.27 | Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse. ( Garba, MT; Hott, M; Marie, PJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 11 (42.31) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, M | 1 |
| Tam, A | 1 |
| Shapiro, JR | 1 |
| Steiner, RD | 1 |
| Smith, PA | 1 |
| Bober, MB | 1 |
| Hart, T | 1 |
| Cuthbertson, D | 1 |
| Krischer, J | 1 |
| Mullins, M | 1 |
| Bellur, S | 1 |
| Byers, PH | 1 |
| Pepin, M | 1 |
| Durigova, M | 1 |
| Glorieux, FH | 2 |
| Rauch, F | 2 |
| Lee, B | 1 |
| Sutton, VR | 1 |
| Nagamani, SCS | 1 |
| Yoon, SH | 2 |
| Sugamori, KS | 1 |
| Grynpas, MD | 2 |
| Mitchell, J | 2 |
| Chen, J | 1 |
| Carvalho, PB | 1 |
| Gonçalves, AF | 1 |
| Alegre, PH | 1 |
| Azevedo, PS | 1 |
| Roscani, MG | 1 |
| Bergamasco, CM | 1 |
| Modesto, PN | 1 |
| Fernandes, AA | 1 |
| Minicucci, MF | 1 |
| Paiva, SA | 1 |
| Antonio, L | 1 |
| Zornoff, M | 1 |
| Polegato, BF | 1 |
| Dayer, R | 2 |
| Brennan, TC | 1 |
| Rizzoli, R | 3 |
| Ammann, P | 3 |
| Zeitlin, L | 1 |
| Plotkin, H | 1 |
| Elmann-Larsen, B | 1 |
| Schmitt, D | 1 |
| Zacharin, M | 1 |
| Kanumakala, S | 1 |
| Mekraldi, S | 1 |
| Toromanoff, A | 1 |
| Aström, E | 1 |
| Jorulf, H | 1 |
| Söderhäll, S | 1 |
| Badoud, I | 1 |
| Jagger, CJ | 1 |
| Chambers, TJ | 4 |
| Chow, JW | 3 |
| Rosen, HN | 1 |
| Sullivan, EK | 1 |
| Middlebrooks, VL | 1 |
| Zeind, AJ | 1 |
| Gundberg, C | 1 |
| Dresner-Pollak, R | 1 |
| Maitland, LA | 1 |
| Hock, JM | 1 |
| Moses, AC | 1 |
| Greenspan, SL | 1 |
| Abe, T | 2 |
| Lean, JM | 2 |
| Gallagher, AC | 1 |
| Tobias, JH | 1 |
| Azuma, Y | 1 |
| Oue, Y | 1 |
| Kanatani, H | 1 |
| Ohta, T | 1 |
| Kiyoki, M | 1 |
| Komoriya, K | 1 |
| Yaghoobian, J | 1 |
| Morieux, C | 1 |
| Denne, MA | 1 |
| Bouizar, Z | 1 |
| Ureña, P | 1 |
| de Vernejoul, MC | 1 |
| Suzuki, M | 1 |
| Adachi, K | 1 |
| Sugimoto, T | 1 |
| Nakayama, H | 1 |
| Doi, K | 1 |
| Kapitola, J | 1 |
| Zák, J | 1 |
| Lacinová, Z | 1 |
| Justová, V | 1 |
| Zeni, S | 1 |
| Gomez-Acotto, C | 1 |
| Mautalen, C | 1 |
| Okada, M | 1 |
| Noguchi, S | 1 |
| Hasegawa, Y | 1 |
| Inukai, T | 1 |
| Golomb, G | 1 |
| Eitan, Y | 1 |
| Hoffman, A | 1 |
| Cal, JC | 1 |
| Daley-Yates, PT | 1 |
| Wingen, F | 1 |
| Sterz, H | 1 |
| Blum, H | 1 |
| Möller, H | 1 |
| Pittermann, W | 1 |
| Pool, BL | 1 |
| Sinn, HJ | 1 |
| Spring, H | 1 |
| Schmähl, D | 1 |
| Marie, PJ | 1 |
| Hott, M | 1 |
| Garba, MT | 1 |
3 trials available for pamidronate and Body Weight
| Article | Year |
|---|---|
Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Densit | 2016 |
Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Body Height; Body Weight; Bone and Bones; | 2004 |
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Ch | 2007 |
23 other studies available for pamidronate and Body Weight
| Article | Year |
|---|---|
Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study.
Topics: Adolescent; Adult; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Diphosphonate | 2019 |
Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Remodeling; Bone Resorption; Calcification, Phys | 2016 |
Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats.
Topics: Animals; Body Weight; Calcium; Cardiotoxicity; Diastole; Diphosphonates; Doxorubicin; Drinking Behav | 2016 |
PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone Density Conservation Agents; | 2010 |
Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Topics: Adolescent; Aging; Body Height; Body Weight; Bone and Bones; Bone Density; Child; Child Development; | 2003 |
Staying in bed to benefit ESA's astronauts and Europe's citizens.
Topics: Adaptation, Physiological; Aerospace Medicine; Bed Rest; Body Weight; Bone Density; Bone Resorption; | 2003 |
Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet.
Topics: Amino Acids; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density; Diet, Protein-Restricte | 2005 |
Defective implant osseointegration under protein undernutrition: prevention by PTH or pamidronate.
Topics: Animal Feed; Animals; Body Weight; Diphosphonates; Female; Implants, Experimental; Osseointegration; | 2007 |
Stimulation of bone formation by dynamic mechanical loading of rat caudal vertebrae is not suppressed by 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP).
Topics: Animals; Body Weight; Bone Development; Bone Resorption; Diphosphonates; Female; Pamidronate; Rats; | 1995 |
Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; C | 1993 |
Estrogen does not restore bone lost after ovariectomy in the rat.
Topics: Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Diphospho | 1993 |
Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Resorption; Dihydrotestosterone; Diphosphonates; Female; | 1996 |
Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Diphosphon | 1998 |
Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
Topics: Adenylyl Cyclases; Animals; Anti-Inflammatory Agents; Blotting, Northern; Body Weight; Bone Resorpti | 1998 |
The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate.
Topics: Animals; Body Weight; Bone Marrow; Bone Resorption; Calcium; Diphosphonates; Femur; Granulocyte Colo | 1999 |
Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.
Topics: Amino Acids; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Cardiac Output; Di | 2000 |
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Ra | 2001 |
Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol.
Topics: Animals; Body Weight; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Female; Hypercalcemia; P | 1992 |
Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.
Topics: Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Resorption; Diphosphonates; Femur; | 1992 |
The anabolic action of 17 beta-estradiol (E2) on rat trabecular bone is suppressed by (3-amino-1-hydroxypropylidene)-1-bisphosphonate (AHPrBP).
Topics: Animals; Body Weight; Bone and Bones; Bone Development; Bone Resorption; Diphosphonates; Estradiol; | 1992 |
Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice.
Topics: Acetylglucosaminidase; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Creatinine; Dipho | 1990 |
Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.
Topics: Animals; Antineoplastic Agents; Body Temperature; Body Weight; Bone and Bones; Bone Development; Bro | 1986 |
Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse.
Topics: Acid Phosphatase; Animals; Body Weight; Bone Development; Bone Matrix; Bone Resorption; Calcium; Dip | 1985 |